Clarient, Inc (CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, announced that the company is to begin the commercialization of a novel breast cancer test. This new offering, titled ‘Clarient Insigh Dx Breast Cancer Profile’, is to be sold through an exclusive license agreement with Prediction Sciences, a La Jolla, CA-based company.
This new breast cancer profile, the most significant test to date in Clarient’s novel marker program, is the first product in Clarient’s Insight Dx line of molecular tests. These tests are being commercialized to provide valuable cancer characterization information for prognosis and therapy selection for the major cancer types.
The new breast cancer profile has already undergone rigorous validation. Various results have shown that this test yields excellent accuracy and substantial out-performance of standard treatment guidelines.
Ron Andrews, CEO and President of Clarient, stated, “This new agreement provides Clarient with an important addition to our breast cancer menu — a new molecular diagnostic test that we believe predicts the likelihood of disease recurrence, and ultimately the benefit of chemotherapy for patients. Along with its significant value for the over 35,000 breast cancer patients we expect to test this year, Clarient’s Insight Dx Breast Cancer Profile has the potential to deliver a significant economic opportunity for the company.”
Cornelius Diamond, Chief Executive Officer of Prediction Sciences, added, “We are excited to have entered into this agreement with Clarient. The Clarient Insight Dx Breast Cancer Profile is the first in a pipeline of tests developed by Prediction Sciences that we believe will significantly improve and personalize patient care. We believe that Clarient is well positioned to commercialize this test and provide invaluable benefit to breast cancer patients and their physicians, allowing them to make informed treatment decisions.”
Let us hear your thoughts below: